Estrella Immunopharma, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $32.0M
- Price
- $0.7353
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.30%
- Volume
- 8.2K
About
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.
Quick stats
Shares outstanding43.5M
Computed float15.1M
Float / shares34.8%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001844417
Websitehttps://www.estrellabio.com
AI Summary
AI-generated1/12
minorbullishclinical trial
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma activated University Hospitals Cleveland Medical Center as the fourth clinical site for its ongoing Phase I/II STARLIGHT-1 trial of EB103 in relapsed or refractory B-cell non-Hodgkin’s lymphoma.
The expansion cohort is designed to evaluate safety and efficacy at the recommended Phase II dose, with data expected to inform the pivotal trial strategy.
Active sites now include UC Davis, Baylor Scott & White, Oregon Health & Science University, and UH Cleveland.